Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 7, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 357,250 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,618.00 pence per share; lowest price paid was 1,596.50 pence per share.
- Treasury Holdings (Settled): 487,433,663 shares (9.12% of total issued share capital).
- Treasury Holdings (Including Unsettled): 488,327,913 shares (10.05% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,857,259,181 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 357,250 shares for treasury. Consequently, the total number of shares held in treasury increased, raising the percentage of total voting rights held in treasury to 10.05% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a routine disclosure confirming compliance with the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership notifications.
Investor Verification Checklist
- Verify the total number of shares in issue (4,857,259,181) for calculating disclosure thresholds under FCA rules.
- Confirm the current percentage of voting rights held in treasury (10.05% including unsettled shares).
- Note that this filing does not contain operational or financial performance data for the period.